242 related articles for article (PubMed ID: 11532635)
41. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
42. Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure.
Nishio M; Nakao S; Endo T; Fujimoto K; Takashima H; Sakai T; Bacigalupo A; Koike T; Sawada K
Bone Marrow Transplant; 2001 Oct; 28(8):783-5. PubMed ID: 11781631
[TBL] [Abstract][Full Text] [Related]
43. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
Okuda S; Terasako K; Oshima K; Sato M; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
Am J Hematol; 2009 Mar; 84(3):167-9. PubMed ID: 19195036
[TBL] [Abstract][Full Text] [Related]
44. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
[TBL] [Abstract][Full Text] [Related]
45. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies.
Shin DY; Lee JH; Park S; Lee JO; Moon JH; Ahn JS; Choi Y; Song IC; Shin HJ; Lee WS; Lee HS; Yoon SS
Bone Marrow Transplant; 2018 Feb; 53(2):207-212. PubMed ID: 29084202
[TBL] [Abstract][Full Text] [Related]
46. FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Ashizawa M; Kako S; Wada H; Sakamoto K; Sato M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Kanda Y
Hematol Oncol; 2012 Mar; 30(1):50-2. PubMed ID: 21574175
[No Abstract] [Full Text] [Related]
47. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
[TBL] [Abstract][Full Text] [Related]
49. Acute left ventricular failure following melphalan and fludarabine conditioning.
Ritchie DS; Seymour JF; Roberts AW; Szer J; Grigg AP
Bone Marrow Transplant; 2001 Jul; 28(1):101-3. PubMed ID: 11498753
[TBL] [Abstract][Full Text] [Related]
50. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
51. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
52. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
53. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
54. Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis.
Chen Y; Xu LP; Zhang XH; Chen H; Wang FR; Liu KY; Qin J; Yang YL; Huang XJ
Bone Marrow Transplant; 2018 Jun; 53(6):770-773. PubMed ID: 29725109
[No Abstract] [Full Text] [Related]
55. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Kröger N; Zabelina T; Schieder H; Panse J; Ayuk F; Stute N; Fehse N; Waschke O; Fehse B; Kvasnicka HM; Thiele J; Zander A
Br J Haematol; 2005 Mar; 128(5):690-7. PubMed ID: 15725091
[TBL] [Abstract][Full Text] [Related]
56. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
[TBL] [Abstract][Full Text] [Related]
57. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
58. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
[TBL] [Abstract][Full Text] [Related]
59. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
[TBL] [Abstract][Full Text] [Related]
60. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
